Latest clinical study may shut door on secretin as autism drug

01/6/2004 | NYTimes.com

Repligen announced its latest clinical trial of the drug secretin has failed to prove the efficacy of using it to treat autism. The decision, following the largest and most definitive trial of the drug, casts doubt on whether secretin will ever become a treatment for the childhood disease.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA